Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Occupational Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Antiviral Res. 2012 Feb;93(2):239-244. doi: 10.1016/j.antiviral.2011.12.002. Epub 2011 Dec 13.
Both interleukin-28B genetic variants and on-treatment virological responses are factors predictive of treatment outcome in hepatitis C virus genotype 1 (HCV-1) patients. We aimed to compare the clinical significance of the two factors.
Rs8099917 genotype and on-treatment responses were determined in 182 HCV-1 patients with 48-week peginterferon/ribavirin.
Comparing to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, 46.2% vs. 19.2%, P=0.01) and sustained virological response (SVR, 85.3% vs. 42.3%, P<0.001) rates. Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/95% confidence intervals [OR/CI]: 4.25/1.39-13.01). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 57.22/6.23-525.37), followed by the carriage of rs8099917 TT genotype (OR/CI: 10.06/3.12-32.44). However, while on-treatment factors were taken into account, the cEVR was the most important determinant to an SVR (OR/CI:54.98/9.07-333.38), whereas the influence of rs8099917 genotype became non-significant in non-RVR patients.
Rs8099917 TT genotype is significantly independently predictive of on-treatment virological responses, which were the major determinants of an SVR, in Asian HCV-1 patients.
白细胞介素 28B 基因变异和治疗中病毒学应答是丙型肝炎病毒 1 型（HCV-1）患者治疗结果的预测因素。我们旨在比较这两个因素的临床意义。
在 182 例接受 48 周聚乙二醇干扰素/利巴韦林治疗的 HCV-1 患者中，测定了 rs8099917 基因型和治疗中应答。
与 rs8099917TG/GG 基因型患者相比，TT 基因型患者的快速病毒学应答（RVR，46.2% vs. 19.2%，P=0.01）和持续病毒学应答（SVR，85.3% vs. 42.3%，P<0.001）率显著更高。Logistic 回归分析显示，预测 RVR 的最强因素是携带 rs8099917TT 基因型（优势比/95%置信区间[OR/CI]：4.25/1.39-13.01）。预测 SVR 的最重要因素是达到 RVR（OR/CI：57.22/6.23-525.37），其次是携带 rs8099917TT 基因型（OR/CI：10.06/3.12-32.44）。然而，在考虑治疗期间因素的情况下，cEVR 是 SVR 的最重要决定因素（OR/CI：54.98/9.07-333.38），而 rs8099917 基因型的影响在未达到 RVR 的患者中变得不显著。
在亚洲 HCV-1 患者中，rs8099917TT 基因型与治疗中病毒学应答显著独立相关，而治疗中病毒学应答是 SVR 的主要决定因素。
